671802-00-9

Basic information

• Product Name: tert-Butyl 3-(2-hydroxyethoxy)propanoate
• Synonyms: tert-Butyl 3-(2-hydroxyethoxy)propanoate;Hydroxy-PEG1-t-butyl ester;3-(2-Hydroxyethoxy)propanoic acid 1,1-dimethylethyl ester;3-(2-Hydroxyethoxy)propanoic acid tert-butyl ester;HO-PEG1-t-Butyl ester
• CAS NO: 671802-00-9
• Molecular Formula: C₉H₁₈O₄
• Molecular Weight: 190.23682
• Mol File: 671802-00-9.mol

Chemical Properties

• Boiling Point: 274.0±15.0 °C(Predicted)
• Appearance: /
• Density: 1.031±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 14.36±0.10(Predicted)
• CAS DataBase Reference: tert-Butyl 3-(2-hydroxyethoxy)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 3-(2-hydroxyethoxy)propanoate(671802-00-9)
• EPA Substance Registry System: tert-Butyl 3-(2-hydroxyethoxy)propanoate(671802-00-9)

Safety Data

• Hazardous Substances Data: 671802-00-9(Hazardous Substances Data)

Usage

Uses

Used in Organic and Pharmaceutical Synthesis:
tert-Butyl 3-(2-hydroxyethoxy)propanoate is utilized as an organic synthesis intermediate and a pharmaceutical intermediate. It plays a crucial role in the laboratory research and development process, as well as in the production process of pharmaceuticals and chemicals. Its versatility and reactivity make it a valuable component in the synthesis of various compounds.
Used in the Synthesis of Cellobiose Derivatives:
In the field of carbohydrate chemistry, tert-Butyl 3-(2-hydroxyethoxy)propanoate serves as a reactant in the synthesis of hydrophilic aminooxy linked and multivalent disaccharide cellobiose derivatives. These derivatives are essential for chemoselective aldehyde/ketone conjugation, which is a critical step in the development of new drugs and bioactive molecules.
Used in the Chemical Industry:
tert-Butyl 3-(2-hydroxyethoxy)propanoate is also employed in the chemical industry for the synthesis of various compounds and materials. Its unique properties, such as the hydrophilic PEG spacer and the t-butyl protected carboxyl group, make it an attractive candidate for the development of new products with improved properties and applications.

Synthesis

To a solution of anhydrous ethylene glycol (10 g, 161.1 mmol) in anhydrous THF (40 mL) was added sodium metal (62.0 mg, 2.70 mmol) and stirred at room temperature for 2 hours.Add tert-butyl acrylate (6.90, 53.7 mmol) and stir overnight.After quenching with water, the solvent was THF dried under reduced pressure, and extracted with ethyl acetate and water.The organic layer was separated, washed with brine, and dried over Na 2 SO 4.After filtration and evaporation, the residue was purified by silica gel column chromatography (petroleum ether/ethyl acetate = 2:1) to obtain a colorless oil 44 (5.0 g, 26.3 mmol, 49% yield)

Upstream product

• 1663-39-4 tert-Butyl acrylate 
• 107-21-1 ethylene glycol 

Downstream Products

• 1393330-36-3 tert-butyl 3-(2-bromoethoxy)propanoate 
• 65868-63-5 tert-butyl 6-bromohexanoate 
• 1260092-46-3 3-(2-aminoethoxy)propionic acid tert-butyl ester 
• 1309666-78-1 tert-butyl 3-[2-(4-methylphenyl)sulfonyloxyethoxy]propanoate 
• 2307461-45-4 C₂₅H₂₈F₃N₅O₆S 
• 2296723-16-3 tert-butyl 3-(2-iodoethoxy)propanoate 
• 1309666-80-5 C₃₆H₃₆O₈ 
• 1309666-79-2 C₄₄H₅₂O₈ 

Relevant articles and documents

Discovery of the First Examples of Threonine Tyrosine Kinase PROTAC Degraders

The first examples of threonine tyrosine kinase (TTK) PROTACs were designed and synthesized. Two of the most potent molecules, 8e and 8j, demonstrated strong TTK degradation in COLO-205 human colorectal cancer cells with DC50 values of 1.7 and 3.1 nM, respectively. Proteasome-mediated degradation by the compounds could last for approximately 8 h after washout. The degraders 8e and 8j demonstrated improved antiproliferative activities comparing with the structurally similar inhibitor counterparts 8q and 8r. Degraders 8e and 8j also demonstrated reasonable PK profiles and exhibited potent target degradation and in vivo anticancer efficacy in a xenograft mouse model of COLO-205 human colorectal cancer cells upon i.p. administration.

Protein degradation targeting chimera for degrading androgen receptor

The invention relates to a novel difunctional molecule compound based on VHL ligand induction and application of the difunctional molecule compound in synthesis of the compounds and pharmaceutical compositions thereof. The compound is shown as a formula I. The compound can selectively induce AR protein degradation and can be used for treating cancers such as prostatic cancer and breast cancer.

BIFUNCTIONAL SUBSTITUED PYRIMIDINES AS MODULATORS OF FAK PROTEOLYSE

The present disclosure relates to bifunctional compounds, which find utility as modulators of focal adhesion kinase (FAK) or protein tyrosine kinase 2 (PTK2). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Compound for targeted ubiquitination degradation of ERRalpha protein and pharmaceutical composition and application thereof

The invention provides a compound with a structure shown as a formula (I), which has the effects of inhibiting ERRalpha protein activity and degrading ERRalpha protein activity, has relatively strongsubtype selectivity and can also effectively inhibit tri

Identification of New Small-Molecule Inducers of Estrogen-related Receptor α (ERRα) Degradation

A series of (E)-3-(4-((2,4-bis(trifluoromethyl)benzyl)oxy)-3-methoxyphenyl)-2-cyanoacrylamide derivatives were designed and synthesized as new estrogen-related receptor α (ERRα) degraders based on the proteolysis targeting chimera (PROTAC) concept. One of the representative compounds 6c is capable of specifically degrading ERRα protein by >80% at a relatively low concentration of 30 nM, becoming one of the most potent and selective ERRα degraders to date. Compound 6c could be utilized as a new powerful research tool for further biological investigation of ERRα.

Synthesis of Cyclic and Acyclic Nucleoside Phosphonates and Sulfonamides Derived from 6-(Thiophen-2-yl)-7-fluoro-7-deazapurine

Ribonuclosides derived from 6-hetaryl-7-dezapurines are potent cytostatics, but their mechanism of action is unknown. Here we designed and synthesized a series of cyclic and acyclic nucleoside phosphonates, as well as carboxy, cyano, sulfo, and sulfonamide acyclic analogues derived from 6-thiophen-2-yl-7-deazapurine and 7-fluoro-6-thiophen-2-yl-7-deazapurine as ribonucleoside monophosphate mimics. None of these analogues exerted significant cytotoxic and antiviral activity.

BIHETEROCYCLIC COMPOUND

The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X═Y—Z, X—Y═Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.

Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and uses thereof

Disclosed are an antibody drug conjugate IB, which uses ether linkages for connection, and improves the water solubility, stability and cytotoxicity in vivo and in intro, and an intermediate, a pharmaceutical composition, and uses of the antibody drug conjugate. The antibody drug conjugate has simple synthetic steps and a high yield.

Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation

Enzymatic inhibition has proven to be a successful modality for the development of many small-molecule drugs. In recent years, small-molecule-induced protein degradation has emerged as an orthogonal therapeutic strategy that has the potential to expand the druggable target space. Focal adhesion kinase (Fak) is a key player in tumor invasion and metastasis, acting simultaneously as a kinase and a scaffold for several signaling proteins. While previous efforts to modulate Fak activity were limited to kinase inhibitors with low success in clinical studies, protein degradation offers a possibility to simultaneously block Fak's kinase signaling and scaffolding capabilities. Here, we report the development of a selective and potent Fak degrader, PROTAC-3, which outperforms a clinical candidate, defactinib, with respect to Fak activation as well as Fak-mediated cell migration and invasion. These results underline the potential that PROTACs offer in expanding the druggable space and controlling protein functions that are not easily addressed by traditional small-molecule therapeutics.

ANTI-CD70 ANTIBODY DRUG CONJUGATES

This invention relates to anti-CD70 antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are αCD70 antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the αCD70 antibodies of the invention are conjugated to one or more toxins. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, including therapeutic, diagnostic, and other biotechnology uses.